{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00027935", "CSN": null, "TRF": "ORD_1591919_01", "MRN": "26940830", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1295400", "clinicalId": "1296750", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1591919_01", "SampleName": "US1521197.01", "Version": "0", "Sample": {"FM_Id": "ORD_1591919_01", "SampleId": "US1521197.01", "BlockId": "S112-79051", "TRFNumber": "ORD_1591919_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_03_21", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "80", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10076", "MRN": "26940830", "FullName": "\u9673\u6587\u97dc", "FirstName": "Wen_Tao", "LastName": "Chen", "SubmittedDiagnosis": "Skin melanoma", "Gender": "Male", "DOB": "1953_07_02", "OrderingMD": "\u9673\u4ead\u5b89", "OrderingMDId": "109266", "Pathologist": "\u6881\u6587\u8b70", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Rectum", "CollDate": "2023_02_14", "ReceivedDate": "2023-03-31 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Melanoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRAF"}, {"Gene": "KIT"}, {"Gene": "NRAS"}]}, "Summaries": {"alterationCount": "32", "clinicalTrialCount": "9", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ABL1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ALK", "isVUS": "true", "variantName": "V163L"}, {"geneName": "CCND3", "isVUS": "true", "variantName": "amplification"}, {"geneName": "CDKN1A", "isVUS": "true", "variantName": "amplification"}, {"geneName": "CDKN2C", "isVUS": "true", "variantName": "amplification"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "amplification"}, {"geneName": "DDR1", "isVUS": "true", "variantName": "V220M,amplification"}, {"geneName": "FANCC", "isVUS": "true", "variantName": "A325T,amplification"}, {"geneName": "GNAQ", "isVUS": "true", "variantName": "amplification"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "A173P"}, {"geneName": "HDAC1", "isVUS": "true", "variantName": "E461K"}, {"geneName": "IRF4", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MKNK1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MUTYH", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NBN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NSD3 (WHSC1L1)", "isVUS": "true", "variantName": "A458V"}, {"geneName": "NTRK2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PIM1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "RAD21", "isVUS": "true", "variantName": "amplification"}, {"geneName": "RAD54L", "isVUS": "true", "variantName": "amplification"}, {"geneName": "SYK", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "A562V"}, {"geneName": "TSC1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "VEGFA", "isVUS": "true", "variantName": "amplification"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "MYC", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "MYC (c_MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers (Dang et al., 2006; 16904903). MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types (Nesbit et al., 1999; 10378696). MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes (Blancato et al., 2004; 15083194, Dang et al., 2006; 16904903, Fromont et al., 2013; 23574779). MYC amplification has been reported in 6.4% of skin melanomas analyzed in 1 study (cBio_Van Allen et al., 2015; 26359337). Copy number gains (amplification, intermediate increase, or simple gain) of MYC have been found in 11_70% of uveal melanomas and in 63% of hepatic metastatic lesions of primary uveal melanoma (Parrella et al., 2001; 11431428, Harbour, 2012; 22268848, Hoglund et al., 2004; 14618616, Damato et al., 2010; 20975103, Singh et al., 2009; 19653714, Damato et al., 2007; 17719643). MYC amplification has also been shown to correlate with loss of BAP1, with concomitant MYC amplification and BAP1 loss reported in 27% of uveal melanoma cases in 1 study (Damato et al., 2007; 17719643, Parrella et al., 2001; 11431428). Copy number gain of the genomic region that includes MYC has been observed in malignant melanoma cases and was suggested to be associated with a more aggressive clinical course and reduced OS (Pouryazdanparast et al., 2012; 22020039, Pouryazdanparast et al., 2012; 22555175). High MYC protein expression is associated with improved survival for patients with uveal melanoma, which is in contrast to findings in cutaneous melanoma (Chana et al., 1998; 9610866, Chana et al., 1999; 10209447). Limited clinical data indicates that MYC activation may predict sensitivity to the pan_MYC inhibitor OMO_103; a Phase 1 study for patients with solid tumors reported 7 SDs (n=18), including 8% tumor reduction in a patient with pancreas adenocarcinoma (Garralda et al., 2022; ENA Abstract 7). Preclinical data indicate MYC overexpression may predict sensitivity to investigational agents targeting CDK1 (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519), CDK2 (Molenaar et al., 2009; 19525400), Aurora kinase A (Dammert et al., 2019; 31375684, Mollaoglu et al., 2017; 28089889, Robert et al., 2017; 29088717, Wang et al., 2017; 28417568, Takahashi et al., 2015; 25632068, Li et al., 2018; 30226440, Kong et al., 2017; DOI: 10.21037/tcr.2017.06.41, Mahadeva et al., 2014; 24893165, Park et al., 2019; 31429028), Aurora kinase B (Helfrich et al., 2016; 27496133, Hook et al., 2012; 22222631, Yang et al., 2010; 20643922, He et al., 2019; 30540594), glutaminase (Shroff et al., 2015; 25964345, Effenberger et al., 2017; 29156762, Shen et al., 2018; 30103944, Xiang et al., 2015; 25915584), or BET bromodomain_containing proteins (Delmore et al., 2011; 21889194, Bandopadhayay et al., 2013; 24297863, Loven et al., 2013; 23582323, Otto et al., 2019; 31734632), as well as agents targeting both HDAC and PI3K (Dong et al., 2013; 23866964, Pei et al., 2016; 26977882; Fu et al., 2019; 30224636). Exploratory biomarker analysis in a Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second_line therapy for patients with MYC_overexpressed small cell lung cancer, but not for patients without MYC overexpression (Owonikoko et al., 2020; 31655296). A PR was reported for a patient with MYC_amplified invasive ductal breast carcinoma treated with an unspecified Aurora kinase inhibitor and taxol (Ganesan et al., 2014; 25253784). MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies (Pereira et al., 2013; 23555992, Yasojima et al., 2011; 21741827). Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5_fluorouracil and paclitaxel (Arango et al., 2001; 11406570, Bottone et al., 2003; 14516787).", "Include": "true", "ClinicalTrialNote": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05253053", "Include": "true"}, {"nctId": "NCT04983810", "Include": "true"}, {"nctId": "NCT05327010", "Include": "true"}, {"nctId": "NCT05053971", "Include": "true"}, {"nctId": "NCT04555837", "Include": "true"}, {"nctId": "NCT05252390", "Include": "true"}, {"nctId": "NCT04742959", "Include": "true"}, {"nctId": "NCT01434316", "Include": "true"}, {"nctId": "NCT04840589", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "JUN", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "JUN encodes oncogenic transcription factor c_JUN, which belongs to the family of activator protein 1 (AP_1) transcription factors. It is involved in development, proliferation, cell survival, and tumorigenesis (Meng and Xia, 2011; 22180088, Angel et al., 1991; 1751545, Shaulian et al., 2002; 11988758, Trierweiler et al., 2016; 26470729 ). Amplification of JUN has been correlated with increased protein expression (Snyder et al., 2009; 19449367, Mariani et al., 2007; 17418412, Spruill et al., 2002; 12515591). In large_scale datasets, JUN amplification has been reported in 7% of sarcomas and at lower frequencies in other solid tumors (cBioPortal, 2023) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Studies have reported JUN amplification in 18_24% of dedifferentiated liposarcoma (DDLPS) samples but not in well_differentiated liposarcomas (WDLPS) (cBio_Barretina et al., 2010; 20601955, Tap et al., 2011; 21117066), and it is implicated in the progression of liposarcoma from WDLPS to DDLPS (Mariani et al., 2007; 17418412, Tap et al., 2011; 21117066, Snyder et al., 2009; 19449367). High levels of c_JUN expression have been reported in 47% (7/15) of high_grade central osteosarcomas (Franchi et al., 1998; 9672192), 45_53% of ovarian epithelial cancer tissues (Yokoyama et al., 1999; 10680335, Yokoyama et al., 1998; 9570981), and 60% (30/50) of tongue cancer cases (Gupta et al., 2015; 26581505). Constitutive expression of c_JUN protein was reported in 91% (39/43) of renal cell carcinoma (RCC) primary tumors (Koo et al., 1992; 1404666); high phosphorylated c_JUN levels in hepatocellular carcinoma (HCC) were associated with poor OS and decreased response to sorafenib (Hagiwara et al., 2012; 22596232, Chen et al., 2016; 26964667). Expression of c_JUN has been positively correlated with tumor grade and epithelial_mesenchymal transition in breast and endometrial tumors (Bircan et al., 2005; 15800680, Ouelaa_Benslama et al., 2012; 22552300). There are no approved therapies or clinical trials to address JUN alterations.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 16_32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI_low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20_77%) compared to primary tumors (2_30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Johnson et al., 2016; 27671167, Goodman et al., 2017; 28835386, Eroglu et al, 2018; 29320474, Shin et al., 2017; 27903500, Riaz et al., 2017; 29033130, Cristescu et al., 2018; 30309915, Samstein et al., 2019; 30643254, Ribas et al., 2019; AACR abstract 4217, Hodi et al., 2019; AACR abstract CT037, Marabelle et al., 2020; 32919529). A large_scale genomic analysis found that various melanoma subtypes harbored median TMBs between 6.3 and 14.4 Muts/Mb, and 25% to 40% of cases had elevated TMBs of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types (Alexandrov et al., 2013; 23945592), with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)(Shain et al., 2015; 26343386). Higher mutational load has been reported in NF1_mutant melanoma samples compared with BRAF_mutant, NRAS_mutant, or BRAF/NRAS/NF1 wild_type samples (Johnson et al., 2016; 27671167). In 1 study, elevated TMB correlated with PD_L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti_PD_1 or anti_PD_L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_1 or anti_PD_L1 treatments (Hodi et al., 2019; AACR Abstract CT037, Ribas et al., 2019; AACR Abstract 4217, Cristescu et al., 2018; 30309915, Johnson et al., 2016; 27671167, Ning et al., 2022; 35355708). Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency >8 Muts/Mb as measured by this assay) (Hodi et al., 2019; AACR abstract CT037). Increased TMB (~equivalency >10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab (Hodi et al., 2019; AACR abstract CT037). Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels (Ribas et al., 2019; AACR abstract 4217, Liu et al., 2019; 31515453).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "MYC", "Alteration": "amplification", "Title": "Study to Evaluate the Efficacy and Safety of TT_00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, Aurora kinase B, PD_L1", "Locations": "Jinan (China), Beijing (China)", "NCTID": "NCT05253053", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma", "StudyPhase": "PHASE 1/2", "Target": "CDK2, CDK9", "Locations": "Seoul (Korea, Republic of), Barcelona (Spain), California, Texas", "NCTID": "NCT04983810", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Testing the Combination of the Anti_cancer Drugs ZEN003694 (ZEN_3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial", "StudyPhase": "PHASE 2", "Target": "PARP, BRD4, BRDT, BRD2, BRD3", "Locations": "Illinois, Texas, North Carolina, Georgia", "NCTID": "NCT05327010", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Testing A New Anti_cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1/2", "Target": "BRD3, BRD4, BRD2, BRDT, HDAC", "Locations": "Oklahoma, Connecticut, Florida", "NCTID": "NCT05053971", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, PD_1", "Locations": "Texas", "NCTID": "NCT04555837", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "NUV_868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRD4, PARP, AR", "Locations": "Montana, California, Arizona, Michigan, Texas, Tennessee, Maryland, Virginia, North Carolina", "NCTID": "NCT05252390", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Crossover Relative Bioavailability and Dose Escalation Study of TT_00420 Tablet in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, Aurora kinase B", "Locations": "California, Illinois, Ohio, Texas, New Jersey", "NCTID": "NCT04742959", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PARP, CDK1, CDK9, CDK5, CDK2", "Locations": "Massachusetts", "NCTID": "NCT01434316", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, CTLA_4, BRD4, BRDT, BRD2, BRD3", "Locations": "Ohio, Pennsylvania, New York, Maryland", "NCTID": "NCT04840589", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "16904903", "FullCitation": "Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903", "Include": "true"}, {"number": "1", "ReferenceId": "10378696", "FullCitation": "Nesbit CE, et al. Oncogene (1999) pmid: 10378696", "Include": "true"}, {"number": "2", "ReferenceId": "15083194", "FullCitation": "Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194", "Include": "true"}, {"number": "3", "ReferenceId": "23574779", "FullCitation": "Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779", "Include": "true"}, {"number": "4", "ReferenceId": "26359337", "FullCitation": "Van Allen EM, et al. Science (2015) pmid: 26359337", "Include": "true"}, {"number": "5", "ReferenceId": "11431428", "FullCitation": "Parrella P, et al. Invest. Ophthalmol. Vis. Sci. (2001) pmid: 11431428", "Include": "true"}, {"number": "6", "ReferenceId": "22268848", "FullCitation": "Pigment Cell Melanoma Res (2012) pmid: 22268848", "Include": "true"}, {"number": "7", "ReferenceId": "14618616", "FullCitation": "H\u00f6glund M, et al. Int. J. Cancer (2004) pmid: 14618616", "Include": "true"}, {"number": "8", "ReferenceId": "20975103", "FullCitation": "Damato B, et al. Clin. Cancer Res. (2010) pmid: 20975103", "Include": "true"}, {"number": "9", "ReferenceId": "19653714", "FullCitation": "Singh AD, et al. Arch. Pathol. Lab. Med. (2009) pmid: 19653714", "Include": "true"}, {"number": "10", "ReferenceId": "17719643", "FullCitation": "Damato B, et al. Ophthalmology (2007) pmid: 17719643", "Include": "true"}, {"number": "11", "ReferenceId": "22020039", "FullCitation": "Pouryazdanparast P, et al. Am. J. Surg. Pathol. (2012) pmid: 22020039", "Include": "true"}, {"number": "12", "ReferenceId": "22555175", "FullCitation": "Pouryazdanparast P, et al. Mod. Pathol. (2012) pmid: 22555175", "Include": "true"}, {"number": "13", "ReferenceId": "9610866", "FullCitation": "Chana JS, et al. Melanoma Res. (1998) pmid: 9610866", "Include": "true"}, {"number": "14", "ReferenceId": "10209447", "FullCitation": "Chana JS, et al. Br J Ophthalmol (1999) pmid: 10209447", "Include": "true"}, {"number": "15", "ReferenceId": "22430491", "FullCitation": "Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491", "Include": "true"}, {"number": "16", "ReferenceId": "17589519", "FullCitation": "Goga A, et al. Nat. Med. (2007) pmid: 17589519", "Include": "true"}, {"number": "17", "ReferenceId": "19525400", "FullCitation": "Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400", "Include": "true"}, {"number": "18", "ReferenceId": "31375684", "FullCitation": "Dammert MA, et al. Nat Commun (2019) pmid: 31375684", "Include": "true"}, {"number": "19", "ReferenceId": "28089889", "FullCitation": "Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889", "Include": "true"}, {"number": "20", "ReferenceId": "29088717", "FullCitation": "Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717", "Include": "true"}, {"number": "21", "ReferenceId": "28417568", "FullCitation": "Wang L, et al. Mol Oncol (2017) pmid: 28417568", "Include": "true"}, {"number": "22", "ReferenceId": "25632068", "FullCitation": "Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068", "Include": "true"}, {"number": "23", "ReferenceId": "30226440", "FullCitation": "Li Y, et al. Thyroid (2018) pmid: 30226440", "Include": "true"}, {"number": "24", "ReferenceId": "24893165", "FullCitation": "Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165", "Include": "true"}, {"number": "25", "ReferenceId": "31429028", "FullCitation": "Park SI, et al. Target Oncol (2019) pmid: 31429028", "Include": "true"}, {"number": "26", "ReferenceId": "27496133", "FullCitation": "Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133", "Include": "true"}, {"number": "27", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "28", "ReferenceId": "20643922", "FullCitation": "Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922", "Include": "true"}, {"number": "29", "ReferenceId": "30540594", "FullCitation": "He J, et al. Anticancer Drugs (2019) pmid: 30540594", "Include": "true"}, {"number": "30", "ReferenceId": "25964345", "FullCitation": "Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345", "Include": "true"}, {"number": "31", "ReferenceId": "29156762", "FullCitation": "Effenberger M, et al. Oncotarget (2017) pmid: 29156762", "Include": "true"}, {"number": "32", "ReferenceId": "30103944", "FullCitation": "Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944", "Include": "true"}, {"number": "33", "ReferenceId": "25915584", "FullCitation": "Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584", "Include": "true"}, {"number": "34", "ReferenceId": "21889194", "FullCitation": "Delmore JE, et al. Cell (2011) pmid: 21889194", "Include": "true"}, {"number": "35", "ReferenceId": "24297863", "FullCitation": "Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863", "Include": "true"}, {"number": "36", "ReferenceId": "23582323", "FullCitation": "Lov\u00e9n J, et al. Cell (2013) pmid: 23582323", "Include": "true"}, {"number": "37", "ReferenceId": "31734632", "FullCitation": "Otto C, et al. Neoplasia (2019) pmid: 31734632", "Include": "true"}, {"number": "38", "ReferenceId": "23866964", "FullCitation": "Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964", "Include": "true"}, {"number": "39", "ReferenceId": "26977882", "FullCitation": "Pei Y, et al. Cancer Cell (2016) pmid: 26977882", "Include": "true"}, {"number": "40", "ReferenceId": "30224636", "FullCitation": "Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636", "Include": "true"}, {"number": "41", "ReferenceId": "31655296", "FullCitation": "Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296", "Include": "true"}, {"number": "42", "ReferenceId": "25253784", "FullCitation": "Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784", "Include": "true"}, {"number": "43", "ReferenceId": "23555992", "FullCitation": "Pereira CB, et al. PLoS ONE (2013) pmid: 23555992", "Include": "true"}, {"number": "44", "ReferenceId": "21741827", "FullCitation": "Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827", "Include": "true"}, {"number": "45", "ReferenceId": "11406570", "FullCitation": "Arango D, et al. Cancer Res. (2001) pmid: 11406570", "Include": "true"}, {"number": "46", "ReferenceId": "14516787", "FullCitation": "Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787", "Include": "true"}, {"number": "47", "ReferenceId": "22180088", "FullCitation": "Meng Q, et al. Protein Cell (2011) pmid: 22180088", "Include": "true"}, {"number": "48", "ReferenceId": "1751545", "FullCitation": "Angel P, et al. Biochim. Biophys. Acta (1991) pmid: 1751545", "Include": "true"}, {"number": "49", "ReferenceId": "11988758", "FullCitation": "Shaulian E, et al. Nat. Cell Biol. (2002) pmid: 11988758", "Include": "true"}, {"number": "50", "ReferenceId": "26470729", "FullCitation": "Trierweiler C, et al. Cell Death Differ. (2016) pmid: 26470729", "Include": "true"}, {"number": "51", "ReferenceId": "19449367", "FullCitation": "Snyder EL, et al. J. Pathol. (2009) pmid: 19449367", "Include": "true"}, {"number": "52", "ReferenceId": "17418412", "FullCitation": "Mariani O, et al. Cancer Cell (2007) pmid: 17418412", "Include": "true"}, {"number": "53", "ReferenceId": "12515591", "FullCitation": "Spruill MD, et al. J. Toxicol. Environ. Health Part A (2002) pmid: 12515591", "Include": "true"}, {"number": "54", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "55", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "56", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "57", "ReferenceId": "21117066", "FullCitation": "Tap WD, et al. Genes Chromosomes Cancer (2011) pmid: 21117066", "Include": "true"}, {"number": "58", "ReferenceId": "9672192", "FullCitation": "Franchi A, et al. Virchows Arch. (1998) pmid: 9672192", "Include": "true"}, {"number": "59", "ReferenceId": "10680335", "FullCitation": "Yokoyama Y, et al. J. Obstet. Gynaecol. Res. (1999) pmid: 10680335", "Include": "true"}, {"number": "60", "ReferenceId": "9570981", "FullCitation": "Yokoyama Y, et al. Gynecol. Oncol. (1998) pmid: 9570981", "Include": "true"}, {"number": "61", "ReferenceId": "26581505", "FullCitation": "Gupta S, et al. Sci Rep (2015) pmid: 26581505", "Include": "true"}, {"number": "62", "ReferenceId": "1404666", "FullCitation": "Koo AS, et al. J. Urol. (1992) pmid: 1404666", "Include": "true"}, {"number": "63", "ReferenceId": "22596232", "FullCitation": "Hagiwara S, et al. Br. J. Cancer (2012) pmid: 22596232", "Include": "true"}, {"number": "64", "ReferenceId": "26964667", "FullCitation": "Chen W, et al. Sci Rep (2016) pmid: 26964667", "Include": "true"}, {"number": "65", "ReferenceId": "15800680", "FullCitation": "Bircan S, et al. Pathol. Oncol. Res. (2005) pmid: 15800680", "Include": "true"}, {"number": "66", "ReferenceId": "22552300", "FullCitation": "Ouelaa_Benslama R, et al. Int. J. Oncol. (2012) pmid: 22552300", "Include": "true"}, {"number": "67", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "68", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "69", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "70", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "71", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "72", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "73", "ReferenceId": "27623135", "FullCitation": "Kube\u010dek O, et al. Melanoma Res. (2016) pmid: 27623135", "Include": "true"}, {"number": "74", "ReferenceId": "27372860", "FullCitation": "Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860", "Include": "true"}, {"number": "75", "ReferenceId": "7561170", "FullCitation": "Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170", "Include": "true"}, {"number": "76", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "77", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "78", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "79", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "80", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "81", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "82", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "83", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "84", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "85", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "86", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "87", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "88", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "89", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "90", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "91", "ReferenceId": "27671167", "FullCitation": "Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167", "Include": "true"}, {"number": "92", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "93", "ReferenceId": "29320474", "FullCitation": "Eroglu Z, et al. Nature (2018) pmid: 29320474", "Include": "true"}, {"number": "94", "ReferenceId": "27903500", "FullCitation": "Shin DS, et al. Cancer Discov (2017) pmid: 27903500", "Include": "true"}, {"number": "95", "ReferenceId": "29033130", "FullCitation": "Riaz N, et al. Cell (2017) pmid: 29033130", "Include": "true"}, {"number": "96", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "97", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "98", "ReferenceId": "32919529", "FullCitation": "Lancet Oncol. (2020) pmid: 32919529", "Include": "true"}, {"number": "99", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "100", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "101", "ReferenceId": "26343386", "FullCitation": "Shain AH, et al. Nat. Genet. (2015) pmid: 26343386", "Include": "true"}, {"number": "102", "ReferenceId": "26960397", "FullCitation": "Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397", "Include": "true"}, {"number": "103", "ReferenceId": "26559571", "FullCitation": "Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571", "Include": "true"}, {"number": "104", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "105", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "106", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "107", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "108", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "109", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "110", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "111", "ReferenceId": "35355708", "FullCitation": "Ning B, et al. Front Pharmacol (2022) pmid: 35355708", "Include": "true"}, {"number": "112", "ReferenceId": "31515453", "FullCitation": "Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_03_28 22:32:51", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "841x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SKIN", "disease_ontology": "Skin melanoma", "flowcell_analysis": "2000028341", "gender": "male", "pathology_diagnosis": "C43, Melanoma", "percent_tumor_nuclei": "80", "pipeline_version": "v3.20.0", "purity_assessment": "80.17", "specimen": "ORD_1591919_01*US1521197.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1591919_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Rectum", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "903.59", "name": "SQ_US1521197.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4822", "cds_effect": "1685C>T", "depth": "732", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "48.22", "position": "chr12:115112055", "protein_effect": "A562V", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"allele_fraction": "0.6844", "cds_effect": "517G>C", "depth": "808", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "68.44", "position": "chr20:57415678", "protein_effect": "A173P", "status": "unknown", "strand": "+", "transcript": "NM_016592", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"allele_fraction": "0.0788", "cds_effect": "487G>T", "depth": "914", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "7.88", "position": "chr2:30143039", "protein_effect": "V163L", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"allele_fraction": "0.6965", "cds_effect": "973G>A", "depth": "1206", "equivocal": "false", "functional_effect": "missense", "gene": "FANCC", "percent_reads": "69.65", "position": "chr9:97887391", "protein_effect": "A325T", "status": "unknown", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"allele_fraction": "0.3485", "cds_effect": "658G>A", "depth": "1805", "equivocal": "false", "functional_effect": "missense", "gene": "DDR1", "percent_reads": "34.85", "position": "chr6:30859249", "protein_effect": "V220M", "status": "unknown", "strand": "+", "transcript": "NM_001954", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"allele_fraction": "0.1552", "cds_effect": "1373C>T", "depth": "567", "equivocal": "false", "functional_effect": "missense", "gene": "WHSC1L1", "percent_reads": "15.52", "position": "chr8:38187104", "protein_effect": "A458V", "status": "unknown", "strand": "_", "transcript": "NM_023034", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"allele_fraction": "0.1732", "cds_effect": "1381G>A", "depth": "410", "equivocal": "false", "functional_effect": "missense", "gene": "HDAC1", "percent_reads": "17.32", "position": "chr1:32798310", "protein_effect": "E461K", "status": "unknown", "strand": "+", "transcript": "NM_004964", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "11", "equivocal": "true", "gene": "RAD21", "number_of_exons": "13 of 13", "position": "chr8:117859738_117878968", "ratio": "2.25", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "NBN", "number_of_exons": "16 of 16", "position": "chr8:90947760_90996835", "ratio": "2.22", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "VEGFA", "number_of_exons": "8 of 8", "position": "chr6:43738443_43752419", "ratio": "1.9", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "10", "equivocal": "true", "gene": "MKNK1", "number_of_exons": "13 of 13", "position": "chr1:47024246_47059866", "ratio": "2.09", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "SYK", "number_of_exons": "13 of 13", "position": "chr9:93606180_93657910", "ratio": "1.68", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "GNAQ", "number_of_exons": "7 of 7", "position": "chr9:80336238_80646151", "ratio": "1.74", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "DDR1", "number_of_exons": "18 of 18", "position": "chr6:30852937_30867073", "ratio": "2.3", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "CDKN2C", "number_of_exons": "5 of 5", "position": "chr1:51435639_51441400", "ratio": "1.76", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "NOTCH1", "number_of_exons": "34 of 34", "position": "chr9:139390522_139440272", "ratio": "1.93", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "CDKN1A", "number_of_exons": "2 of 2", "position": "chr6:36651878_36653617", "ratio": "2.23", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "FANCC", "number_of_exons": "15 of 15", "position": "chr9:97863988_98011573", "ratio": "1.75", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "10", "equivocal": "true", "gene": "RAD54L", "number_of_exons": "18 of 18", "position": "chr1:46714014_46743954", "ratio": "2.12", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "10", "equivocal": "true", "gene": "MUTYH", "number_of_exons": "16 of 16", "position": "chr1:45794977_45805973", "ratio": "2.14", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "PTCH1", "number_of_exons": "25 of 25", "position": "chr9:98209193_98279102", "ratio": "1.76", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "TSC1", "number_of_exons": "21 of 21", "position": "chr9:135771621_135804270", "ratio": "1.92", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "CCND3", "number_of_exons": "5 of 5", "position": "chr6:41903677_41909387", "ratio": "2.01", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "PIM1", "number_of_exons": "7 of 7", "position": "chr6:37138078_37141867", "ratio": "2.24", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "IRF4", "number_of_exons": "8 of 8", "position": "chr6:393152_407598", "ratio": "2.27", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "DAXX", "number_of_exons": "8 of 8", "position": "chr6:33286484_33290730", "ratio": "2.27", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "ABL1", "number_of_exons": "12 of 12", "position": "chr9:133589706_133761070", "ratio": "1.91", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "10", "equivocal": "true", "gene": "JUN", "number_of_exons": "3 of 3", "position": "chr1:59246464_59249785", "ratio": "2.08", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "11", "equivocal": "true", "gene": "MYC", "number_of_exons": "5 of 5", "position": "chr8:128748789_128753204", "ratio": "2.3", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "NTRK2", "number_of_exons": "18 of 18", "position": "chr9:87285663_87636352", "ratio": "1.79", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1521197.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}